Scandinavian Journal of Pain
Volume 1, Supplement 1 , Pages S12-S17, May 2009

New therapeutic principles for adverse effects on upper and lower gastrointestinal tract in patients treated with opioid analgesics

University of Oslo and Rikshospitalet, Department of Anaesthesiology and Intensive Care, 0027 Oslo, Norway

Article Outline

Abstract 

Recent large scale surveys document that patients on opioid analgesics suffer adverse effects from increased tone in sphincters of both the upper and lower part of the gastrointestinal tract, decreased secretions into and increased absorption of fluids out of the bowel. These adverse effects often cause patients to discontinue opioid analgesics. Also patients treated with opioids for acute pain after surgery and in the intensive care units suffer gastrointestinal adverse effects. Constipation is the most common adverse effect of opioids. Most patients self-medicate with over-the-counter laxatives but suffer unpredictable responses and bothersome adverse effects of laxatives. Potent prescription laxatives may further adversely impact quality of life of chronic pain patients. Opioid-induced dysfunctions of the upper gastrointestinal tract are often misinterpreted by health care providers, and they are not relieved by laxatives.

Two therapeutic developments make specific and effective prophylaxis and treatment possible: (1) Peripherally acting opioid antagonists that do not cross the blood brain barrier (methylnaltrexone and alvimopan), and (2) the opioid antagonist naloxone added to an opioid agonist in prolonged-release oral formulations (tilidin or oxycodone). Orally administered prolonged-release naloxone is almost completely eliminated during the first-pass through the liver and will therefore not reach opioid receptors in the central nervous system. These drugs relieve both upper and lower gastrointestinal adverse effects of opioid agonists, although their effects on constipation have been the focus of most clinical studies. These new pharmacological principles promise improved management of pain with opioids both for acute and chronic pain conditions.

Keywords:  opioids , adverse effects , gastrointestinal dysfunctions , methylnaltrexone , naloxone , constipation

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Allan L , Hays H , Jensen NH , LePolain de Waroux B , Bolt M , Donald R , et al.   Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain . Br Med J . 2001;322:1154–1158
  2. Allan L , et al.   Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain . Spine . 2005;30:2484–2490
  3. Ballantyne JC , LaForge KS . Opioid dependence and addiction during opioid treatment of chronic pain . Pain . 2007;129:235–255
  4. Bell TJ , Panchal SJ , Miaskowski C , Bolge SC , Milanova T , Williamson R . The prevalence, severity, and impact of opioid-induced bowelk dysfunction: Results of a US and European patient survey (PROBE 1) . Pain Med . 2009;10:35–42
  5. Breivik H , Cherny N , Collett B , deConno F , Filbet M , Foubert AJ , et al.   Cancer-related pain: a pan-European survey of prevalence, treatment and patient attitudes . Ann Oncol . 2009 Feb 26; [Epub ahead of print]
  6. Brennscheidt U , Seiler KU , Thomann P . Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilitine/naloxone sustained release tablets . Arzneimittelforschung . 2000;50:1015–1022
  7. Brennscheidt U , Brunnmüller U , Proppe D , Thomann P , Seiler KU . Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment . Arzneimittelforschung . 2007;57:106–111
  8. Chou R , Fanciullo GJ , Fine PG , Adler JA , Ballantyne JC , Davies P , et al.   Opioid Treatment Guidelines: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain . J Pain . 2009;10:113–130
  9. Colvin L , Forbes K , Fallon M . The difficult pain . Br Med J . 2006;332:1081–1083
  10. Cook SF , Lanza L , Zhou X , Sweeney CT , Goss D , Hollis K , et al.   Gastrointestinal side effects in chronic opioid users: results from a population-based survey . Aliment Pharmacol Ther . 2008;27:1224–1232
  11. Culpepper-Morgan JA , Inturissi CE , Portenoy RK , Foley K , Houde RW , Marsh F , et al.   Treatment of opioid-induced constipation with oral naloxone: a pilot study . Clin Pharmacol Ther . 1992;52:90–95
  12. De Schepper HU , Cremonini F , Park MI , Camilleri M . Opioids and the gut: pharmacology and current clinical experience . Neurogastroenterol Motil . 2004;16:383–394
  13. DeLuca A , Coupar IM . Insights into opioid action in the intestinal tract . Pharmacol Ther . 1996;69:103–112
  14. Delaney CP . Clinical perspective on postoperative ileus and the effect of opiates . Neurogastroenterol Motil (Suppl 2) . 2004;16:61–66
  15. Fahy C , Gan TJ . Postoperative bowel dysfunction . In:  Yuan C-S editors. Handbook of opioid bowel syndrome . London: Haworth Medical Press; 2005;p. 121–153
  16. Holzer P . New approaches to the treatment of opioid-induced constipation . Eur Rev Med Pharmacol Sci . 2008;12(Suppl 1):119–127
  17. Kalso E , Edwards JE , Moore RA , McQuay HJ . Opioids in chronic non-cancer pain: systematic reviewof efficacy and safety . Pain . 2004;112:372–380
  18. Kurz A , Sessler DI . Opioid-induced bowel dysfunction: pathophysiology and potential new therapies . Drugs . 2003;63:649–671
  19. Ling GS , Paul D , Simantov R , Pasternak GW . Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model . Life Sci . 1989;45:1627–1636
  20. Ludwig K , Enker WE , Delaney CP , Wolff BG , Du W , Fort JG , et al.   Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway . Arch Surg . 2008;143:1098–1105
  21. McNicol E , Horowicz-Mehler N , Fisk RA , et al.   Management of opioid side-effects in cancer-related and chronic noncancer pain: a systematic review . J Pain . 2003;4:231–256
  22. McNicol E , Boyce DB , Schumann R , Carr D . Efficacy and safety of mu-opioid anatagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials . Pain Med . 2008;9:634–659
  23. Meissner W , Leyendecker P , Mueller-Lissner S , Nadstawek J , Hopp M , Ruckes C , et al.   A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation . Eur J Pain . 2009;13:56–64
  24. Mythen MG . Postoperative gastrointestinal tract dysfunction . Anesth Analg . 2005;100:196–204
  25. Paulson DM , Kennedy DT , Donovick RA , Carpenter RL , Cherubini M , Techner L , et al.   Alvimopan: an oral, peripherally acting, muopioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment randomized clinical trial . J Pain . 2005;6:184–192
  26. Portenoy RK , Thomas J , Moehl Boatwright ML , Tran D , Galasso FL , Stambler N , et al.   Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study . J Pain Symptom Manage . 2008;35:458–468
  27. Quigley C . The role of opioids in cancer pain . Br Med J . 2005;331:825–828
  28. Reimer K , Hopp M , Zenz M , Maier C , Holzer P , Mikus G , et al.   Meeting the challenges of opioid-induced constipation in chronic pain management a novel approach . Pharmacology . 2009;83:10–17
  29. Russell J , Bass P , Goldberg LI , Schuster CR , Merz H . Antagonism of gut, but not central effects of morphine with quarternary narcotic antagonists . Eur J Pharmacol . 1982;78:255–261
  30. Schook JE , Pelton JT , Hruby VJ , Burks TF . Peptide opioid anatagonist separates peripheral and central opioid antitransit effects . J Pharmacol Exp Ther . 1987;243:492–500
  31. Swegle JM , Logemann C . Management of common opioid-induced adverse effects . Am Fam Physician . 2006;74:1347–1354
  32. Taguchi A , Sharma N , Saleem RM , Sessler DI , Carpenter RL , Seyedsadr M , et al.   Selective postoperative inhibition of gastrointestinal opioid receptors . N Engl J Med . 2001;345:935–940
  33. Thomas J , Karver S , Cooney GA , Chamberlain BH , Watt CK , Slatkin NE , et al.   Methylnaltrexone for opioid-induced constipation in advanced illness . N Engl J Med . 2008;358:23321–23343
  34. Thorpe DM . Management of opioid-induced constipation . Curr Pain Headache Rep . 2001;5:237–240
  35. Vodracova D , Leyendecker P , Meissner W , Hopp M , Szombati I , Hermanns K , et al.   Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain . J Pain . 2008;9:1144–1154
  36. Webster L , Jansen JP , Peppin J , Lasko B , Irving G , Morlion B , et al.   Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain . Pain . 2008;137:428–440
  37. Weinstein SH , Pfeffer M , Schor JM , Indindoli L , Mintz M . Metabolites of naloxone in human urine . J Pharm Sci . 1971;60:1567–1568

PII: S1877-8860(09)70004-7

doi:10.1016/S1877-8860(09)70004-7

Scandinavian Journal of Pain
Volume 1, Supplement 1 , Pages S12-S17, May 2009

Article Tools